Healthtech funding in Q2 2013
European Healthtech startup funding raised during Q2 2013.
In Q2 2013, 31 European Healthtech companies closed 32 funding rounds and raised €244M in equity funding (excluding debt and grants), up 78.4% versus Q2 2012. Finland led by capital raised, and Lanzadera was the most active investor. Data as of 6 Nov 2026.
Equity funding
€244M
+78.4% vs Q2 2012 · excl. debt & grants
Funding rounds
32
+68.4% vs Q2 2012
Companies
31
Top country
Finland
Rank among sectors
#1
21.2% of sector funding
Top-10 round share
93.1%
of disclosed capital
Rounds ≥ €100M
1
Funding by month
€ raised vs rounds, by monthHealthtech — funding by month, Q2 2013 — interactive chart.
Data table
| Funding | Rounds | |
|---|---|---|
| Apr | €153M | 12 |
| May | €79M | 9 |
| Jun | €124M | 11 |
Top countries
by € raisedHealthtech — top countries by capital, Q2 2013 — interactive chart.
Data table
| Healthtech — top countries by capital, Q2 2013 | |
|---|---|
| Finland | €111M |
| France | €59M |
| Switzerland | €43M |
| Denmark | €41M |
| UK | €33M |
| Ireland | €33M |
| Spain | €25M |
| Israel | €12M |
Stage mix
by € raisedHealthtech — stage mix, Q2 2013 — interactive chart.
Data table
| Healthtech — stage mix, Q2 2013 | |
|---|---|
| Grant | €112M |
| Series C | €81M |
| Series B | €50M |
| Growth/Late | €41M |
| Series A | €34M |
| Series D+ | €18M |
| Other | €9.1M |
| Early VC | €8.8M |
| Seed | €2.5M |
Top deals
largest disclosed rounds in Q2 2013| Company | Stage | Date | Amount |
|---|---|---|---|
| Biotie Therapies | Grant | Jun 2013 | €111M |
| Symphogen | Growth/Late | May 2013 | €41M |
| Auris Medical | Series C | Apr 2013 | €40M |
| Opsona | Series C | Apr 2013 | €33M |
| GenSight Biologics | Series A | Apr 2013 | €32M |
| STAT-Diagnostica | Series B | May 2013 | €22M |
| Genticel | Series D+ | Apr 2013 | €18M |
| Phagenesis | Series B | May 2013 | €15M |
| Treato | Series B | Apr 2013 | €11M |
| Dysis Medical | Early VC | Apr 2013 | €8.8M |
| Horizon Discovery | Series C | Jun 2013 | €8.1M |
| Sofinnova Partners | Other | Apr 2013 | €8.0M |
| Biocartis | Grant | Jun 2013 | €1.8M |
| InSphero | Series B | Jun 2013 | €1.6M |
| Minoryx Therapeutics | Series A | Apr 2013 | €1.5M |
Top investors
most active in Q2 2013, by deal count- Lanzadera2 deals
- Parkwalk Advisors2 deals
- Sofinnova Partners2 deals
- Wayra2 deals
- Abingworth LLP1 deals
- Alven Capital1 deals
- Amgen Ventures1 deals
- Amundi Private Equity Funds1 deals
- Boehringer Ingelheim Venture Fund1 deals
- Cabiedes & Partners1 deals